SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc.verified

SABS

Price:

$2.72

Market Cap:

$25.10M

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic...[Read more]

Industry

Biotechnology

IPO Date

2021-02-09

Stock Exchange

NASDAQ

Ticker

SABS

The PE Ratio as of May 2024 (TTM) for SAB Biotherapeutics, Inc. (SABS) is -0.40

According to SAB Biotherapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.40. This represents a change of -71.20% compared to the average of -1.39 of the last 4 quarters.

SAB Biotherapeutics, Inc. (SABS) Historical PE Ratio (quarterly & annually)

How has SABS PE Ratio performed in the past?

The mean historical PE Ratio of SAB Biotherapeutics, Inc. over the last ten years is -94.05. The current -0.40 PE Ratio has changed -57.47% with respect to the historical average. Over the past ten years (40 quarters), SABS's PE Ratio was at its highest in in the March 2021 quarter at 757.04. The PE Ratio was at its lowest in in the September 2021 quarter at -1143.07.

Quarterly (TTM)
Annual

Average

-94.05

Median

-1.37

Minimum

-468.57

Maximum

12.81

SAB Biotherapeutics, Inc. (SABS) PE Ratio by Quarter and Year

Discovering the peaks and valleys of SAB Biotherapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 0%

Maximum Annual PE Ratio = 12.81

Minimum Annual Increase = -195.55%

Minimum Annual PE Ratio = -468.57

Quarterly (TTM)
Annual
YearPE RatioChange
2023-0.90-34.28%
2022-1.37-88.81%
2021-12.24-195.55%
202012.81-102.73%

SAB Biotherapeutics, Inc. (SABS) Average PE Ratio

How has SABS PE Ratio performed in the past?

The current PE Ratio of SAB Biotherapeutics, Inc. (SABS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-4.84

5-year avg

-94.05

10-year avg

-94.05

SAB Biotherapeutics, Inc. (SABS) PE Ratio vs. Peers

How is SABS’s PE Ratio compared to its peers?

SAB Biotherapeutics, Inc.’s PE Ratio is less than Comera Life Sciences Holdings, Inc. (0), less than Processa Pharmaceuticals, Inc. (-0.01), greater than Fresh Tracks Therapeutics, Inc. (-4.52), greater than Third Harmonic Bio, Inc. (-0.95), greater than Cingulate Inc. (-37.73), less than Anebulo Pharmaceuticals, Inc. (-0.17), greater than Cadrenal Therapeutics, Inc. Common Stock (-5.87), greater than Monopar Therapeutics Inc. (-1.36), greater than Unicycive Therapeutics, Inc. (-1.32), greater than Quoin Pharmaceuticals, Ltd. (-0.89), less than Cardio Diagnostics Holdings, Inc. (-0.18), greater than Virax Biolabs Group Limited (-1.26), less than PaxMedica, Inc. Common Stock (-0.23), less than null (-0.01),

Build a custom stock screener for SAB Biotherapeutics, Inc. (SABS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like SAB Biotherapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

SAB Biotherapeutics, Inc. (SABS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like SAB Biotherapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is SAB Biotherapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for SAB Biotherapeutics, Inc. (SABS)?

What is the highest PE Ratio for SAB Biotherapeutics, Inc. (SABS)?

What is the 3-year average PE Ratio for SAB Biotherapeutics, Inc. (SABS)?

What is the 5-year average PE Ratio for SAB Biotherapeutics, Inc. (SABS)?

How does the current PE Ratio for SAB Biotherapeutics, Inc. (SABS) compare to its historical average?